Cargando…

Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension

AIMS: Repeated risk assessments and treatment patterns over long time are sparsely studied in chronic thromboembolic pulmonary hypertension (CTEPH); thus, we aimed to investigate changes in risk status and treatment patterns in incident patients with CTEPH over a 5 year period. METHODS AND RESULTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjellström, Barbro, Bouzina, Habib, Björklund, Erik, Beaudet, Amélie, Edwards, Susan C., Hesselstrand, Roger, Jansson, Kjell, Nisell, Magnus, Rådegran, Göran, Sandqvist, Anna, Wåhlander, Håkan, Hjalmarsson, Clara, Söderberg, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715829/
https://www.ncbi.nlm.nih.gov/pubmed/35789127
http://dx.doi.org/10.1002/ehf2.14033
_version_ 1784842544667951104
author Kjellström, Barbro
Bouzina, Habib
Björklund, Erik
Beaudet, Amélie
Edwards, Susan C.
Hesselstrand, Roger
Jansson, Kjell
Nisell, Magnus
Rådegran, Göran
Sandqvist, Anna
Wåhlander, Håkan
Hjalmarsson, Clara
Söderberg, Stefan
author_facet Kjellström, Barbro
Bouzina, Habib
Björklund, Erik
Beaudet, Amélie
Edwards, Susan C.
Hesselstrand, Roger
Jansson, Kjell
Nisell, Magnus
Rådegran, Göran
Sandqvist, Anna
Wåhlander, Håkan
Hjalmarsson, Clara
Söderberg, Stefan
author_sort Kjellström, Barbro
collection PubMed
description AIMS: Repeated risk assessments and treatment patterns over long time are sparsely studied in chronic thromboembolic pulmonary hypertension (CTEPH); thus, we aimed to investigate changes in risk status and treatment patterns in incident patients with CTEPH over a 5 year period. METHODS AND RESULTS: Descriptive and explorative study including 311 patients diagnosed with CTEPH 2008–2019 from the Swedish pulmonary hypertension registry, stratified by pulmonary endarterectomy surgery (PEA). Risk and PH‐specific treatment were assessed in surgically treated (PEA) and medically treated (non‐PEA) patients at diagnosis and up to 5 years follow‐up. Data are presented as median (Q1–Q3), count or per cent. Prior to surgery, 63% in the PEA‐group [n = 98, age 64 (51–71) years, 37% female] used PH‐specific treatment and 20, 69, and 10% were assessed as low, intermediate or high risk, respectively. After 1 year post‐surgery, 34% had no PH‐specific treatment or follow‐up visit registered despite being alive at 5 years. Of patients with a 5 year visit (n = 23), 46% were at low and 54% at intermediate risk, while 91% used PH‐specific treatment. In the non‐PEA group [n = 213, age 72 (65–77) years, 56% female], 28% were assessed as low, 61% as intermediate and 11% as high risk. All patients at high risk versus 50% at low risk used PH‐specific treatment. The 1 year mortality was 6%, while the risk was unchanged in 57% of the patients; 14% improved from intermediate to low risk, and 1% from high to low risk. At 5 years, 27% had a registered visit and 28% had died. Of patients with a 5 year visit (n = 58), 38% were at low, 59% at intermediate and 1% at high risk, and 86% used PH‐specific treatment. CONCLUSIONS: Risk status assessed pre‐surgery did not foresee long‐term post‐PEA risk and pre‐surgery PH‐specific treatment did not foresee long‐term post‐PEA treatment. Medically treated CTEPH patients tend to remain at the same risk over time, suggesting a need for improved treatment strategies in this group.
format Online
Article
Text
id pubmed-9715829
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97158292022-12-05 Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension Kjellström, Barbro Bouzina, Habib Björklund, Erik Beaudet, Amélie Edwards, Susan C. Hesselstrand, Roger Jansson, Kjell Nisell, Magnus Rådegran, Göran Sandqvist, Anna Wåhlander, Håkan Hjalmarsson, Clara Söderberg, Stefan ESC Heart Fail Original Articles AIMS: Repeated risk assessments and treatment patterns over long time are sparsely studied in chronic thromboembolic pulmonary hypertension (CTEPH); thus, we aimed to investigate changes in risk status and treatment patterns in incident patients with CTEPH over a 5 year period. METHODS AND RESULTS: Descriptive and explorative study including 311 patients diagnosed with CTEPH 2008–2019 from the Swedish pulmonary hypertension registry, stratified by pulmonary endarterectomy surgery (PEA). Risk and PH‐specific treatment were assessed in surgically treated (PEA) and medically treated (non‐PEA) patients at diagnosis and up to 5 years follow‐up. Data are presented as median (Q1–Q3), count or per cent. Prior to surgery, 63% in the PEA‐group [n = 98, age 64 (51–71) years, 37% female] used PH‐specific treatment and 20, 69, and 10% were assessed as low, intermediate or high risk, respectively. After 1 year post‐surgery, 34% had no PH‐specific treatment or follow‐up visit registered despite being alive at 5 years. Of patients with a 5 year visit (n = 23), 46% were at low and 54% at intermediate risk, while 91% used PH‐specific treatment. In the non‐PEA group [n = 213, age 72 (65–77) years, 56% female], 28% were assessed as low, 61% as intermediate and 11% as high risk. All patients at high risk versus 50% at low risk used PH‐specific treatment. The 1 year mortality was 6%, while the risk was unchanged in 57% of the patients; 14% improved from intermediate to low risk, and 1% from high to low risk. At 5 years, 27% had a registered visit and 28% had died. Of patients with a 5 year visit (n = 58), 38% were at low, 59% at intermediate and 1% at high risk, and 86% used PH‐specific treatment. CONCLUSIONS: Risk status assessed pre‐surgery did not foresee long‐term post‐PEA risk and pre‐surgery PH‐specific treatment did not foresee long‐term post‐PEA treatment. Medically treated CTEPH patients tend to remain at the same risk over time, suggesting a need for improved treatment strategies in this group. John Wiley and Sons Inc. 2022-07-04 /pmc/articles/PMC9715829/ /pubmed/35789127 http://dx.doi.org/10.1002/ehf2.14033 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Kjellström, Barbro
Bouzina, Habib
Björklund, Erik
Beaudet, Amélie
Edwards, Susan C.
Hesselstrand, Roger
Jansson, Kjell
Nisell, Magnus
Rådegran, Göran
Sandqvist, Anna
Wåhlander, Håkan
Hjalmarsson, Clara
Söderberg, Stefan
Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
title Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
title_full Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
title_fullStr Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
title_full_unstemmed Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
title_short Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
title_sort five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715829/
https://www.ncbi.nlm.nih.gov/pubmed/35789127
http://dx.doi.org/10.1002/ehf2.14033
work_keys_str_mv AT kjellstrombarbro fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT bouzinahabib fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT bjorklunderik fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT beaudetamelie fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT edwardssusanc fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT hesselstrandroger fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT janssonkjell fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT nisellmagnus fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT radegrangoran fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT sandqvistanna fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT wahlanderhakan fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT hjalmarssonclara fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension
AT soderbergstefan fiveyearriskassessmentandtreatmentpatternsinpatientswithchronicthromboembolicpulmonaryhypertension